ATE374246T1 - Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter - Google Patents

Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter

Info

Publication number
ATE374246T1
ATE374246T1 AT00969109T AT00969109T ATE374246T1 AT E374246 T1 ATE374246 T1 AT E374246T1 AT 00969109 T AT00969109 T AT 00969109T AT 00969109 T AT00969109 T AT 00969109T AT E374246 T1 ATE374246 T1 AT E374246T1
Authority
AT
Austria
Prior art keywords
catalase
helicobacter
terminal part
polypeptide fragments
polypeptide
Prior art date
Application number
AT00969109T
Other languages
English (en)
Inventor
Christopher Doidge
Elizabeth Webb
Linda Rothel
Philip Sutton
Stuart Hazell
Original Assignee
Csl Ltd
Univ New South Wales
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd, Univ New South Wales filed Critical Csl Ltd
Application granted granted Critical
Publication of ATE374246T1 publication Critical patent/ATE374246T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00969109T 1999-10-15 2000-10-13 Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter ATE374246T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ3471A AUPQ347199A0 (en) 1999-10-15 1999-10-15 Novel polypeptide fragments

Publications (1)

Publication Number Publication Date
ATE374246T1 true ATE374246T1 (de) 2007-10-15

Family

ID=3817627

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00969109T ATE374246T1 (de) 1999-10-15 2000-10-13 Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter

Country Status (10)

Country Link
US (1) US7786260B1 (de)
EP (1) EP1222255B1 (de)
JP (1) JP2003512048A (de)
AT (1) ATE374246T1 (de)
AU (1) AUPQ347199A0 (de)
CA (1) CA2387392A1 (de)
DE (1) DE60036555T2 (de)
HK (1) HK1047960B (de)
NZ (1) NZ518772A (de)
WO (1) WO2001029198A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60045870D1 (de) * 1999-10-29 2011-06-01 Wakamoto Pharma Co Ltd Monoklonaler antikörper, hybridoma, immuntestverfahren und diagnosekit
WO2002004017A2 (en) * 2000-07-07 2002-01-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for preparing oral vaccines
JP5095065B2 (ja) * 2000-08-11 2012-12-12 わかもと製薬株式会社 ヘリコバクター・ピロリ感染の検査方法及び診断キット
JP4763149B2 (ja) * 2001-05-10 2011-08-31 わかもと製薬株式会社 ヘリコバクター・ピロリへの感染を判定する検査方法
US8105615B2 (en) 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
DK2552410T3 (en) 2010-03-31 2019-02-18 Stabilitech Biopharma Ltd PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES
EP2898890B1 (de) 2010-03-31 2019-08-21 Stabilitech Biopharma Ltd Stabilisierung von Virenpartikeln
CA2795047C (en) * 2010-03-31 2019-04-09 Stabilitech Ltd. Stabilised liquid formulations
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3307636B2 (ja) * 1990-01-31 2002-07-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ オクラホマ 自己免疫疾患のためのアッセイおよび治療
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
WO1996033220A1 (en) * 1995-04-21 1996-10-24 Csl Limited Protective helicobacter antigens
EP0745674B1 (de) * 1995-06-02 2006-07-05 Eisai Co., Ltd. Helicobacter Polypeptide, deren Herstellung und Verwendung
AU1055497A (en) * 1995-11-17 1997-06-11 Astra Aktiebolag Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US6551779B1 (en) * 1996-05-31 2003-04-22 Tosiro Sugiyama Helicobactor catalase nucleotide sequences, their production and use
US20050063987A1 (en) * 1996-07-26 2005-03-24 Chiron Behring Gmbh & Co Proteins, in particular membrane proteins, of Helicobacter pylori, their preparation and use
DE19630390A1 (de) * 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
AU3762397A (en) 1996-08-15 1998-03-06 Csl Limited Treatment and prevention of helicobacter infection
WO1998018323A1 (en) * 1996-10-28 1998-05-07 Astra Aktiebolag Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
US20040052799A1 (en) * 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
EP0964699A4 (de) * 1996-12-05 2005-04-06 Astrazeneca Ab Nukleinsäure- und aminosäuresequenzen von heliobacter pylori und impfstoffzusammensetzungen davon
CA2286306A1 (en) * 1997-04-01 1998-10-08 Human Genome Sciences, Inc. Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
EP1173560A1 (de) * 1999-04-30 2002-01-23 Hybrigenics S.A. Ansammlung von prokaryotischen dna für two-hybrid systeme helicobacter pylori protein-protein-wechselwirkungen und verwendung davon

Also Published As

Publication number Publication date
JP2003512048A (ja) 2003-04-02
HK1047960B (en) 2008-04-25
DE60036555T2 (de) 2008-06-26
DE60036555D1 (de) 2007-11-08
EP1222255B1 (de) 2007-09-26
WO2001029198A1 (en) 2001-04-26
AUPQ347199A0 (en) 1999-11-11
HK1047960A1 (en) 2003-03-14
EP1222255A1 (de) 2002-07-17
US7786260B1 (en) 2010-08-31
CA2387392A1 (en) 2001-04-26
EP1222255A4 (de) 2004-03-31
NZ518772A (en) 2003-03-28

Similar Documents

Publication Publication Date Title
ATE335078T1 (de) Überexpression von säugetier- und virusproteinen
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
DK0759944T3 (da) Forbedringer af og relateret til peptidfremføring
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
AR001731A1 (es) Nueva celulasa método para producirla composición que la contiene vector que comprende al adn que lacodifica celula huesped método de aplicación
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
DE69838143D1 (de) Antimikrobielle peptide
ATE317904T1 (de) Überexpression von phytase in hefesystemen
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
ATE322503T1 (de) Gefrierschutzprotein
DE3587875D1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
DK0769056T3 (da) Ikke-splejsende verianter af gp350/220
DE59712235D1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
PT90739A (pt) Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
ATE103930T1 (de) Modifizierte proteine.
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
EP0723016A3 (de) Leukocyten-aktivierender Faktor
DE59009060D1 (de) Überexpression von Proteinen in rekombinanten Wirtszellen.
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
DK1158050T3 (da) Human cysteinyl-leukotrienreceptor (CysLT2)
NO872151D0 (no) Krystallinske, aminobeskyttede aminosyrer og fremgangsmaate for deres fremstilling.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties